GlaxoSmithKline PLC (GSK) Earns News Sentiment Score of 0.04
News headlines about GlaxoSmithKline PLC (NYSE:GSK) have been trending somewhat positive on Wednesday, Accern Sentiment reports. The research group rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. GlaxoSmithKline PLC earned a media sentiment score of 0.04 on Accern’s scale. Accern also gave news articles about the pharmaceutical company an impact score of 45.7093208859369 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the media stories that may have impacted Accern’s rankings:
- Buy Consensus rating on Healthcare Stock: Catabasis Pharmaceuticals, Inc. (CATB) ,GlaxoSmithKline plc (GSK) – Street Observer (press release) (streetobserver.com)
- Emergent Completes Acquisition of Anthrax Drug Raxibacumab (finance.yahoo.com)
- Emergent BioSolutions Completes Acquisition of Raxibacumab, an FDA-Approved Anthrax Monoclonal Antibody, From GSK (finance.yahoo.com)
- Supreme Court declines to hear GSK appeal in Paxil birth defect case – Reuters (reuters.com)
- US judge dismisses ex-sleuths’ lawsuit against GlaxoSmithKline – Reuters (reuters.com)
Shares of GlaxoSmithKline PLC (GSK) traded down 0.34% during mid-day trading on Wednesday, reaching $40.80. The company had a trading volume of 5,537,444 shares. The company has a market capitalization of $99.72 billion, a price-to-earnings ratio of 39.53 and a beta of 1.03. GlaxoSmithKline PLC has a 12 month low of $37.20 and a 12 month high of $44.54. The firm’s 50-day moving average is $39.99 and its 200 day moving average is $41.66.
GlaxoSmithKline PLC (NYSE:GSK) last announced its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.02. The firm had revenue of $9.36 billion for the quarter, compared to the consensus estimate of $9.52 billion. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%. On average, equities research analysts predict that GlaxoSmithKline PLC will post $2.87 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 12th. Shareholders of record on Friday, August 11th will be given a dividend of $0.491 per share. This represents a $1.96 dividend on an annualized basis and a yield of 4.81%. The ex-dividend date is Wednesday, August 9th. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. GlaxoSmithKline PLC’s payout ratio is 197.00%.
Several research analysts have weighed in on the company. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Friday, June 16th. Citigroup Inc. lowered GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a report on Wednesday, July 5th. Zacks Investment Research lowered GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Friday, July 21st. BidaskClub lowered GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a report on Monday, July 24th. Finally, TheStreet lowered GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a report on Wednesday, July 26th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $44.67.
About GlaxoSmithKline PLC
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Stock Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related stocks with our FREE daily email newsletter.